Amylin Pharmaceuticals, Inc. and Eli Lilly and Company BYETTA  ( exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos  ( pioglitazone ), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.